The current NCCN guidelines support the use of targeted therapy in the first line setting for advanced NSCLC with actionable genomic alterations involving EGFR, ALK, ROS1, BRAF, NTRK1/2/3, METex14 skipping, and RET. After disease progression, chemoimmunotherapy is recommended for this population based on the guidelines (2). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.